Yantai Dongcheng Biochemicals Co., Ltd. Class A

As of June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A carries a market capitalization of 10.35B, placing it among publicly traded companies globally. Its enterprise value stands at 11.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Yantai Dongcheng Biochemicals Co., Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A has 824.60M shares outstanding.

As of June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 50.59. The price-to-sales ratio is 3.82, and the price-to-book ratio stands at 2.35.

As of June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A trades at an EV/EBITDA multiple of 50.24 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 50.24 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 11.71B versus a market cap of 10.35B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.68, indicating elevated leverage, while an interest coverage ratio of 2.30 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A posted a return on equity (ROE) of 4.59, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.56 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.28, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.90, useful for judging operating efficiency across full business cycles. The company generates approximately 1.06M in revenue per employee across its workforce of 2,554.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.47 indicates how many times Yantai Dongcheng Biochemicals Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A recorded 65.89M in income tax expense. That works out to an effective tax rate of 28.44, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 231.66M, leaving 204.17M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A's stock has declined approximately 7.27% over the past 52 weeks. The 50-day moving average sits at 12.95, while the 200-day moving average is 13.19.

Over the twelve months ended June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A generated 2.70B in revenue and converted that into 204.17M in net income, yielding earnings per share of 0.20. EBITDA reached 233.16M, while operating income came in at 419.85M.

As of June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A holds 884.41M in cash and equivalents against 1.32B in total debt, resulting in a net debt position of 345.50M. Total book value stands at 4.40B, with working capital of 793.47M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A posted a gross margin of 51.69, reflecting its pricing power and cost economics. The operating margin of 15.53 and net profit margin of 7.55 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A paid dividends of 0.23 per share. The dividend payout ratio of 149.15 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -3.36, meaning Yantai Dongcheng Biochemicals Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Yantai Dongcheng Biochemicals Co., Ltd. Class A's most recent stock split took place on August 30, 2016 with a 1:3 split ratio.

As of June 30, 2026, Yantai Dongcheng Biochemicals Co., Ltd. Class A has an Altman Z-Score of 2.77, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.